We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants.
- Authors
Liu, Jianying; Liu, Yang; Xia, Hongjie; Zou, Jing; Weaver, Scott C.; Swanson, Kena A.; Cai, Hui; Cutler, Mark; Cooper, David; Muik, Alexander; Jansen, Kathrin U.; Sahin, Ugur; Xie, Xuping; Dormitzer, Philip R.; Shi, Pei-Yong
- Abstract
BNT162b2-elicited human sera neutralize the currently dominant Delta SARS-CoV-2 variant. Here, we report the ability of 20 human sera, drawn 2 or 4 weeks after two doses of BNT162b2, to neutralize USA-WA1/2020 SARS-CoV-2 bearing variant spikes from Delta plus (Delta-AY.1, Delta-AY.2), Delta-∆144 (Delta with the Y144 deletion of the Alpha variant), Lambda, B.1.1.519, Theta, and Mu lineage viruses. Geometric mean plaque reduction neutralization titers against Delta-AY.1, Delta-AY.2, and Mu viruses are slightly lower than against USA-WA1/2020, but all sera neutralize the variant viruses to titers of ≥80, and neutralization titers against the Delta-∆144, Lambda, B.1.1.519 and Theta variants not significantly reduced relative to those against USA-WA1/2020. The susceptibility of Delta plus, Lambda, B.1.1.519, Theta, Mu, and other variants to neutralization by the sera indicates that antigenic change has not led to virus escape from vaccine-elicited neutralizing antibodies and supports ongoing mass immunization with BNT162b2 to control the variants and to minimize the emergence of new variants.
- Subjects
SARS-CoV-2; SARS-CoV-2 Delta variant; IMMUNOGLOBULINS; VIRAL antibodies; COVID-19 vaccines; TITERS
- Publication
NPJ Vaccines, 2022, Vol 7, Issue 1, p1
- ISSN
2059-0105
- Publication type
Article
- DOI
10.1038/s41541-022-00462-4